This is a smoking cessation treatment study. Half of all study participants will receive standard smoking cessation therapy including nicotine replacement patches and asked to participate in a 75 minute virtual exercise. All participants will be asked to provide daily logs of smoking behavior for 28 days.

Many people who use e-cigarettes want to quit vaping; however, there is a lack of research on how to support e-cigarette quit attempts. This study will collect information on how e-cigarette users and their medical providers feel about quitting vaping and what strategies might work. We will also test how well nicotine replacement therapy (patches and lozenges), alongside a self-help booklet based off quitting smoking, work in helping people reduce or quit their e-cigarette use.

Cigarette smoking is a significant public health concern. Transcranial magnetic stimulation (TMS) is a non-invasive form of brain stimulation that has already displayed remarkable potential for producing novel, non-pharmacological interventions for depression and cigarette smokers. In this study, we will use brain MRI to guide TMS therapy for smoking cessation.

The aim of the proposed study is to assess how adding messaging to cigarette packages about filter vents and filters influences respondents awareness of filter ventilation, beliefs about the function of filter vents and filters, smoking behavior, ratings of cigarette satisfaction, smoking topography, exposure to nicotine and carbon monoxide, perceptions about the risk of smoking, and intention to stop smoking. The protocol will consist of a randomized experiment via two-week field study. We hypothesize that exposing smokers to messages about filter vents and filters will increase awareness and knowledge of the impact of filter ventilation on cigarette smoking behavior and increase intention to stop smoking. Exposure to messages on packs will also lower ratings of cigarette satisfaction but have no significant impact on smoking behavior, topography, and exposure to nicotine and carbon monoxide.

This is a smoking cessation treatment study. Patients who have a cancer or a suspected cancer who will undergo surgical removal of their cancer are eligible to participate in this study. A novel smoking cessation treatment will be provided to half of the participants in the study. All study participants will receive standard smoking cessation therapy including counseling and the nicotine patch.

This is a research study to find out if smoking cessation medications, either varenicline or nicotine replacement products (patches or lozenges), are effective when given to smokers, remotely, as a one-time sample.

Participants will either receive a sample of varenicline, nicotine patches and lozenges, or neither. This will be decided randomly. Participants have a 50%chance of receiving varenicline, a 25% chance of receiving nicotine products, and a 25% chance of receiving neither. If the participant is assigned to a group that receives free samples, they will be mailed to them free of charge. There is no requirement to use them, and it is completely up to the participants. There is also no requirement to quit in this study.

The study lasts for six months, and will involve six total surveys. In addition, we ask that participants complete daily diaries (about 1 minute each) for the first 4 weeks of the study. Both varenicline and nicotine replacement products are well-established medications that help smokers quit.

The purpose of this project is to understand how different types of non-cigarette tobacco products affect the way smokers use tobacco products. Participants will complete three in-person visits. During the second visit, participants will sample a traditional cigarette and two e-cigarette e-liquids. Participants will answer questionnaires about each product they sample and then complete a preference assessment in which they choose between the products they sampled and their own cigarette. Finally, participants will take home a tobacco product they sampled to use ad libitum (1-week sampling). During the at-home baseline and sampling weeks, participants will complete electronic daily diaries cataloging their tobacco use. Biomarkers (i.e., expired carbon monoxide, cotinine) will corroborate self-reported indices of use. Participation will last approximately two weeks. E-cigarettes are likely less harmful than combustible cigarettes, but we are unsure how harmful, or how safe they might be. Side effects from using the e-cigarette are generally rare and mild, and may include: nausea, headache, heartburn, irritability, anxiety, headache, or trouble sleeping. There is no direct benefit for participating. Participation will aid researchers to determine how different types of tobacco products affect smoking behavior.

The goal of this research is to understand how different types of e-cigarettes affect tobacco use. Participants will either be assigned to a control group that does not receive an e-cigarette or be assigned to receive one of two different types of e-cigarettes to sample in the lab and at home. We will measure participants' smoking and smoke exposure during the study.

Nicotine addiction is a chronic, relapsing brain disorder and although it is the leading cause of preventable premature death in the US, ~20% of adults smoke and among those that try to quit, the majority relapse.Research suggest that nicotine addiction disrupts the working in the brain involved in motivation and reward. The overarching goal of this proposal is to utilize clinical neuroscience to investigate the effects of Mindfulness Oriented Recovery Enhancement (MORE) on modifying behavior to help treat nicotine addiction.

The purpose of this study is to better understand tobacco outcomes using a well-known stop smoking medication, varenicline (Chantix), and financial incentives with tobacco users. We are also interested in how cannabis/marijuana and tobacco interact during a tobacco quit attempt. All participants will receive tobacco cessation treatment (varenicline) for 12 weeks. This study will recruit adult tobacco users (ages 18-40) who are motivated to quit smoking cigarettes.